Last reviewed · How we verify
Daratumumab SC (Darzalex) — Competitive Intelligence Brief
phase 3
Monoclonal antibody
Live · refreshed every 30 min
Target snapshot
Daratumumab SC (Darzalex) (daratumumab-sc-darzalex) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Daratumumab SC (Darzalex) TARGET | daratumumab-sc-darzalex | Pfizer Inc. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Daratumumab SC (Darzalex) CI watch — RSS
- Daratumumab SC (Darzalex) CI watch — Atom
- Daratumumab SC (Darzalex) CI watch — JSON
- Daratumumab SC (Darzalex) alone — RSS
Cite this brief
Drug Landscape (2026). Daratumumab SC (Darzalex) — Competitive Intelligence Brief. https://druglandscape.com/ci/daratumumab-sc-darzalex. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab